دورية أكاديمية
أعرض في EDS

The Burden of Preventable Adverse Drug Events on Hospital Stay and Healthcare Costs in Japanese Pediatric Inpatients: The JADE Study.

التفاصيل البيبلوغرافية
العنوان: The Burden of Preventable Adverse Drug Events on Hospital Stay and Healthcare Costs in Japanese Pediatric Inpatients: The JADE Study.
المؤلفون: Iwasaki H; Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan., Sakuma M; Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan., Ida H; Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan., Morimoto T; Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
المصدر: Clinical medicine insights. Pediatrics [Clin Med Insights Pediatr] 2021 Feb 22; Vol. 15, pp. 1179556521995833. Date of Electronic Publication: 2021 Feb 22 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: SAGE Publications Country of Publication: United States NLM ID: 101595023 Publication Model: eCollection Cited Medium: Print ISSN: 1179-5565 (Print) Linking ISSN: 11795565 NLM ISO Abbreviation: Clin Med Insights Pediatr Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: <2016- > : Thousand Oaks, CA : SAGE Publications
Original Publication: [Auckland, N.Z.] : Libertas Academica
مستخلص: Background: Adverse drug events (ADEs) are a burden to the healthcare system. Preventable ADEs, which was ADEs due to medication errors, could be reduced if medication errors can be prevent or ameliorate.
Objective: We investigated the burden of preventable ADEs on the length of hospital stay (LOS) and costs, and estimated the national burden of preventable ADEs in pediatric inpatients in Japan.
Methods: We analyzed data from the Japan Adverse Drug Events (JADE) study on pediatric patients and estimated the incidence of preventable ADEs and associated extended LOS. Costs attributable to extended LOS by preventable ADEs were calculated using a national statistics database and we calculated the effect of preventable ADEs on national cost excess.
Results: We included 907 patients with 7377 patient-days. Among them, 31 patients (3.4%) experienced preventable ADEs during hospitalization. Preventable ADEs significantly increased the LOS by 14.1 days, adjusting for gender, age, ward, resident physician, surgery during hospitalization, cancer, and severe malformation at birth. The individual cost due to the extended LOS of 14.1 days was estimated as USD 8258. We calculated the annual extra expense for preventable ADEs in Japan as USD 329 676 760. Sensitivity analyses, considering the incidence of preventable ADEs and the length of hospital stay, showed that the expected range of annual extra expense for preventable ADEs in Japan is between USD 141 468 968 and 588 450 708.
Conclusion: Preventable ADEs caused longer hospitalization and considerable extra healthcare costs in pediatric inpatients. Our results would encourage further efforts to prevent and ameliorate preventable ADEs.
Competing Interests: Declaration of conflicting interests:The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Hitoshi Iwasaki is an employee of Novartis Pharma KK. Mio Sakuma, Hiroyuki Ida, and Takeshi Morimoto declare that there is no conflict of interest.
(© The Author(s) 2021.)
References: Paediatr Drugs. 2009;11(2):153-60. (PMID: 19301935)
N Engl J Med. 1991 Feb 7;324(6):370-6. (PMID: 1987460)
JAMA. 1997 Jan 22-29;277(4):301-6. (PMID: 9002492)
Br J Clin Pharmacol. 2004 May;57(5):611-5. (PMID: 15089814)
Int J Clin Pharm. 2018 Jun;40(3):513-519. (PMID: 29603074)
J Paediatr Child Health. 2003 Mar;39(2):124-9. (PMID: 12603801)
Eur J Pediatr. 2015 Oct;174(10):1347-55. (PMID: 25899070)
J Gen Intern Med. 2012 Jul;27(7):801-7. (PMID: 22271271)
Basic Clin Pharmacol Toxicol. 2008 Apr;102(4):408-11. (PMID: 18312492)
Health Policy. 2014 Oct;118(1):127-34. (PMID: 25139708)
Expert Opin Drug Saf. 2018 Jul;17(7):681-695. (PMID: 29952667)
JAMA. 2001 Apr 25;285(16):2114-20. (PMID: 11311101)
J Pharmacol Pharmacother. 2011 Oct;2(4):277-80. (PMID: 22025857)
N Engl J Med. 1991 Feb 7;324(6):377-84. (PMID: 1824793)
BMJ. 2019 Jul 17;366:l4185. (PMID: 31315828)
Qual Saf Health Care. 2010 Feb;19(1):42-7. (PMID: 20172882)
BMC Pharmacol Toxicol. 2018 Jun 25;19(1):34. (PMID: 29941052)
JAMA. 1995 Jul 5;274(1):29-34. (PMID: 7791255)
J Gen Intern Med. 1995 Apr;10(4):199-205. (PMID: 7790981)
Eur J Clin Pharmacol. 2017 Dec;73(12):1539-1549. (PMID: 28871436)
Drug Saf. 2004;27(11):819-29. (PMID: 15350153)
Qual Saf Health Care. 2004 Aug;13(4):306-14. (PMID: 15289635)
Clinicoecon Outcomes Res. 2016 Aug 24;8:413-26. (PMID: 27601925)
JAMA. 1997 Jan 22-29;277(4):307-11. (PMID: 9002493)
BMJ Qual Saf. 2014 Oct;23(10):830-7. (PMID: 24742779)
J Gen Intern Med. 2011 Feb;26(2):148-53. (PMID: 20872082)
Pediatrics. 2018 Sep;142(3):. (PMID: 30097525)
J Clin Pharmacol. 2013 May;53(5):567-73. (PMID: 23553619)
Lancet. 2017 Apr 29;389(10080):1680-1681. (PMID: 28463129)
فهرسة مساهمة: Keywords: Cost; Japanese pediatric inpatients; length of hospital stay; preventable ADEs; quality of healthcare
تواريخ الأحداث: Date Created: 20210322 Latest Revision: 20220421
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7903823
DOI: 10.1177/1179556521995833
PMID: 33746523
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-5565
DOI:10.1177/1179556521995833